Related Experiment Video
Updated: Mar 30, 2026
07:13
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
5.4K
General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study
Marc N Hirt1,2, Aljosha Muttardi1, Thomas M Helms3
1Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Summary
General practitioners (GPs) showed moderate adherence to heart failure (HF) pharmacotherapy guidelines. Improving guideline adherence requires emphasizing mineralocorticoid receptor antagonists (MRAs) and target drug doses.
Area of Science:
- Cardiology
- General Practice
- Pharmacotherapy
Background:
- Adherence to chronic heart failure (HF) pharmacotherapy guidelines improves patient prognosis.
- General practitioners (GPs) manage the majority of HF patients, yet their guideline adherence and prescribing rationales are not well-documented.
Purpose of the Study:
- To assess current guideline adherence for HF pharmacotherapy among GPs.
- To identify factors influencing GPs' prescribing decisions for HF medications.
- To evaluate the impact of addressing documentation deficits and contraindications on guideline adherence.
Main Methods:
- A three-stage study involving analysis of patient records (Stage I), GP interviews (Stage II), and patient interviews (Stage III).
- Quantified prescription rates and doses of ACE-inhibitors/angiotensin receptor blockers (ACEIs/ARBs), beta blockers (BBs), and mineralocorticoid receptor antagonists (MRAs).
- Calculated a guideline adherence indicator (GAI-3) and assessed reasons for non-adherence.
Main Results:
- Initial adherence: 76% ACEIs/ARBs, 73% BBs, 18% MRAs; GAI-3 was 22%.
- After addressing documentation and contraindications: 87% ACEIs/ARBs, 84% BBs; GAI-3 increased to 56%.
- MRAs remained underprescribed despite frequent contraindications; GPs lacked awareness of MRA value and target doses for other drugs. Patient compliance was generally good, with 11% discontinuing medication.
Conclusions:
- GP guideline adherence for HF pharmacotherapy is higher than previously suggested.
- Further improvements can be achieved by emphasizing MRAs as a key drug class and reinforcing the importance of reaching target doses.
- Awareness of MRA's prognostic value and adherence to target doses for ACEIs/ARBs and BBs are crucial for optimizing HF management.
Related Concept Videos
01:30Heart Failure V: Medical Management
532
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532
01:22Heart Failure VI: Adjunct Therapies
568
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
568
01:30Heart Failure VII: Nursing Interventions
718
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
718
01:29Cardiomyopathy V: Interprofessional Care
637
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
637
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:21Rheumatic Heart Disease III: Medical Management
493
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
493